Attività
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Nucleic Acid-focused Technology
100,0
%
| 206 | 100,0 % | 167 | 100,0 % | -19,03% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 206 | 100,0 % | 167 | 100,0 % | -19,03% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 52 | 01/03/13 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 01/01/19 |
Chief Operating Officer | 45 | 01/01/13 | |
Chief Tech/Sci/R&D Officer | 68 | 01/03/23 | |
Neda Safarzadeh
IRC | Investor Relations Contact | - | - |
Lance Kurata
LAW | General Counsel | 54 | 10/08/20 |
Kevin T. Skol
PRN | Corporate Officer/Principal | - | 01/01/02 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Edward W. Holmes
BRD | Director/Board Member | 83 | 01/09/19 |
James F. Barlow
BRD | Director/Board Member | 65 | 27/05/18 |
Peter Farrell
CHM | Chairman | 81 | 27/05/18 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 01/01/19 |
Magda Marquet
BRD | Director/Board Member | 65 | 27/05/18 |
Jing Marantz
BRD | Director/Board Member | 59 | 07/12/21 |
Joseph Payne
CEO | Chief Executive Officer | 52 | 01/03/13 |
John Markels
BRD | Director/Board Member | 58 | 08/12/22 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 26 931 826 | 24 577 248 ( 91,26 %) | 0 | 91,26 % |
Coordinate società
Arcturus Therapeutics Holdings, Inc.
10628 Science Center Drive Suite 250
92121, San Diego
+
http://www.arcturusrx.comSettore
Variaz. 1 gen. | Capi. | |
---|---|---|
+33,69% | 49,46 Mrd | |
+1,63% | 42,58 Mrd | |
+49,11% | 42,49 Mrd | |
-4,22% | 29,09 Mrd | |
+11,25% | 26,61 Mrd | |
-21,12% | 18,64 Mrd | |
+7,41% | 13,16 Mrd | |
+28,94% | 12,55 Mrd | |
+23,52% | 12,1 Mrd |